Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics' stock price has experienced significant volatility and an overall increase in the past year. In Q3 2025, the company reported a significant increase in revenue and a shift to net income. Stifel Nicolaus initiated coverage with a "buy" rating, and Wall Street Zen upgraded shares to a "buy" rating. Major shareholder Rock Ventures IV L.P. Third sold shares in October 2025. Barbara Weber retired as CEO, and Malte Peters was appointed as her successor in January 2026. Sung Lee was appointed to the Board of Directors in January 2026. Tango Therapeutics participated in the J.P. Morgan Healthcare Conference in December 2025. As of January 7, 2026, the share price was $11.79, a significant increase from $3.23 on January 8, 2025.

Information regarding demand seasonality for Tango Therapeutics, Inc.'s products and services is not readily available. The demand for its future products would likely be driven by medical need and clinical efficacy rather than traditional seasonal consumer patterns.

Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering novel drug targets and delivering precision medicine for cancer treatment, operating within the Healthcare sector. The company develops therapies targeting vulnerabilities in cancer cells, aiming to spare normal cells. Its major product candidates include TNG908, TNG260, TNG348, TNG462, and TNG456. The company also has a strategic collaboration with Gilead Sciences, Inc.

Tango Therapeutics is headquartered in Boston, Massachusetts, USA, which serves as the central hub for research and development, clinical operations, and corporate strategy. The company's clinical trials for its drug candidates have a global reach, with collaborations with clinical trial sites and investigators internationally.

Tango Therapeutics' brand reputation has likely been positively influenced by its financial turnaround and positive analyst sentiment. The company reported a significant increase in revenue and a shift to net income in Q3 2025, which could enhance its standing in the biotechnology sector. Analysts have a "Moderate Buy" consensus rating for the stock, indicating a generally positive outlook from the investment community.

Tango Therapeutics, Inc. has substantial institutional ownership, with 263 institutional owners and shareholders holding approximately 89.6% of the company's shares. Major institutional owners include TRV GP IV, LLC, Farallon Capital Management LLC, and EcoR1 Capital, LLC. Other notable holders include Gilead Sciences, Inc., State Street Corp., and Adage Capital Management, L.P. Insiders hold 7.50% of the stock.